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Bortezomib promotes KHSV and 
EBV lytic cycle by activating JNK 
and autophagy
Marisa Granato, Maria Anele Romeo, Mariangela Sara Tiano, Roberta Santarelli, Roberta 
Gonnella, Maria Saveria Gilardini Montani, Alberto Faggioni & Mara Cirone
KSHV and EBV are gammaherpesviruses strictly linked to human cancers. Even if the majority of 
cancer cells harbor a latent infection, the few cells that undergo viral replication may contribute to 
the pathogenesis and maintenance of the virus-associated malignancies. Cytotoxic drugs used for the 
therapies of cancers harboring virus-infection often have, as side effect, the activation of viral lytic 
cycle. Therefore it is important to investigate whether they affect viral reactivation and understand 
the underlying mechanisms involved. In this study, we found that proteasome inhibitor bortezomib, 
a cytotoxic drug that efficiently target gammaherpesvirus-associated B cell lymphomas, triggered 
KSHV or EBV viral lytic cycle by activating JNK, in the course of ER stress, and inducing autophagy. 
These results suggest that the manipulation of these pathways could limit viral spread and improve the 
outcome of bortezomib treatment in patients affected by gammaherpesvirus-associated lymphomas.
Tumor cells arising from Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus 
(KSHV)-associated cancers usually harbor latent infection and the few cells that undergo spontaneous viral rep-
lication promote viral spread and disease maintenance1,2. Viral reactivation can be induced upon appropriate 
stimuli that are usually cytotoxic3, although herpesvirus lytic proteins may partially counteract their cytotoxic 
effects. ER stress is one of the stimuli able to induce the reactivation from latency of KSHV4,5 and EBV6, two 
gammaherpesviruses strictly associated to Primary Effusion Lymphoma (PEL) and endemic Burkitt’s lymphoma 
(eBL), respectively. Endoplasmic Reticulum (ER) stress, triggered by perturbations within the ER that alter pro-
tein folding and processing, leads to the activation of the unfolded protein response (UPR)7. It is initiated by three 
ER transmembrane receptors: protein kinase RNA (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1 
(IRE1α) and activating transcription factor 6 (ATF6) that promote or cell survival or cell death depending on 
the balance between Binding immunoglobulin Protein/(78 kDa glucose regulated protein) (BiP/(GRP78) and C/
EBP-Homologous Protein8. The underlying mechanisms of the ER stress-mediated gammaherpesvirus reactiva-
tion from latency are not fully clarified yet. Activating factor 4 (ATF4) and X-box binding protein 1 (XBP1) have 
been shown to be involved in KSHV replication induced by several ER stressors5. Conversely, in another study, 
IRE1α and PERK, ER stress sensors, is shown to be down regulated in PEL cells during the latent phase. CCAAT/
enhancer-binding protein β (C/EBPβ) molecule, also up-regulated by ER stress9, has been shown to be involved 
in bortezomib-induced EBV lytic cycle activation10. ER stress is indeed induced by bortezomib, a peptide boro-
nate, which inhibits 26 S proteasome leading to the accumulation of misfolded proteins not longer degraded via 
proteasome11. In the course of ER stress induced by bortezomib, c-Jun N-terminal Protein Kinase (JNK) can be 
activated by the IRE1 arm of UPR and may promote autophagy by phosphorylating Bcl-212. Accordingly, we have 
previously shown that bortezomib-induced ER stress promoted a pro-survival autophagy through the activation 
of JNK in PEL cells13. Autophagy is a catabolic process that usually helps cancer cells to survive in stressful con-
ditions such as during starvation or in the course of chemotherapies. Autophagy may also promote the lytic cycle 
of different viruses including gammaherpesviruses14–17. In this study, we investigated whether JNK activation by 
bortezomib could promote viral lytic cycle through autophagy induction in B cells latently infected with EBV or 
KSHV. JNK and the other Mitogen-Activated Protein Kinases (MAPKs) activated by cellular stress18 have been 
reported, in separate studies, to regulate the autophagic pathway19 and promote the viral lytic cycle20,21. However, 
the link between MAPKs and autophagy in the activation of gammaherpesvirus replication by bortezomib has 
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never been explored. Understanding the molecular mechanisms underlying chemotherapy-induced viral reacti-
vation from latency could help to achieve a better control of EBV and KSHV-associated malignancies, since their 
pathogenesis is strictly dependent on both latent and lytic phases of the viral life22–24.
Results
Bortezomib induces KSHV and EBV lytic antigen expression concomitantly with autophagy 
induction in cells undergoing apoptosis. PEL cell lines harboring KSHV (BC3 and BCBL1) or lym-
phoma cells infected by EBV (Raji) or B cells in vitro transformed by the virus (B95-8) were treated with borte-
zomib for the indicated times. We found that in all cell lines, bortezomib induced time-dependent KSHV and/or 
EBV lytic antigen expression that occurred concomitantly with autophagy activation, as indicated by the viral lytic 
protein expression that increased at the same times in which microtubule-associated protein 1 A/1B-light chain 
3-II (LC3-II) accumulated (Fig. 1A). As control, we performed the same kinetic experiment in mock-treated 
Figure 1. Bortezomib triggers KSHV and EBV lytic cycle concomitantly with autophagy induction in viral-
infected B cells. (A) BC3, BCBL1, B95-8 and Raji cells were treated with bortezomib (BZ) (20 nM) for the 
indicated times and K-bZIP KSHV or ZEBRA EBV lytic antigen expression was evaluated by western blot 
analysis. (B) BC3, BCBL1, B95-8 and Raji cells were mock treated for the indicated times and K-bZIP or 
ZEBRA expression was evaluated by western blot analysis. (C) BC3, BCBL1, B95-8 and Raji cells were treated 
with different bortezomib doses (0-10-20 nM) for 24 hours and K-bZIP or ZEBRA lytic antigen expression was 
evaluated by western blot analysis. β-Actin was used as loading control. The histograms represent the mean 
plus standard deviation (SD) of the densitometric analysis of the ratio of specific proteins on β-Actin of three 
different experiments.
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cell lines and, as expected, neither viral lytic antigens nor LC3-II expression increased over time in the control 
treated cells (Fig. 1B). Next, a dose-response experiment indicated that viral KSHV and EBV lytic antigen and 
LC3-II expression were up-regulated as bortezomib dose increased (Fig. 1C). Interestingly, the apoptotic process 
was induced by bortezomib at the same doses at which it triggered viral replication (Fig. 2A). We also found that 
the bortezomib-mediated gammaherpesvirus lytic cycle was complete, as both BC3 and B95-8 cells express the 
KSHV and EBV late lytic antigens K8.1 and gp350, respectively (Fig. 2B). Finally, according to a previous study25, 
when BC3 cells were pretreated with z-VAD, the lytic cycle antigen expression was reduced (Fig. 2C), suggesting 
that caspase activation play a role in the induction of viral replication.
Altogether, these experiments indicate that gammaherpesvirus lytic antigens and autophagy activation 
occurred concomitantly, in time- and dose-dependent fashion, in cells harboring latent KSHV or EBV infection 
undergoing apoptosis upon bortezomib-treatment.
Autophagy is involved in gammaherpesvirus lytic cycle activation by bortezomib. We then 
assessed whether autophagy would play a role in bortezomib-induced lytic cycle. As previously reported for 
TPA/Butyrate (T/B)-induced lytic cycle15,16, we found that the inhibition of the first autophagic steps by 
3-Methyladenine (3-MA) reduced viral lytic antigen expression induced by bortezomib in BC3 and Raji cells 
(Fig. 3A). Differently, when autophagy was blocked at the final phases with the lysomonotropic agent chloro-
quine, that inhibits lysosome acidification, the viral lytic protein expression was slightly affected (Fig. 3A). This 
suggests that the last autophagic steps do not play a role in the KSHV and EBV replicative process, likely due to 
the previous finding that autophagy is blocked at the final steps by gammaherpesvirus lytic antigens15,16. Next, 
Figure 2. Viral replication is induced by bortezomib in cells undergoing apoptosis. (A) BC3 and B95-8 cells 
were treated with the indicated doses of bortezomib for 24 hours and apoptosis occurrence was evaluated by 
FACS analysis as sub-G1 percentage. (B) BC3 and B95-8 cells undergoing 24 hours of bortezomib treatment 
were analysed by western blot for the expression of the late viral proteins K8.1 and gp 350 for KSHV and EBV, 
respectively. α-Tubulin was used as loading control. The histograms represent the mean plus standard deviation 
(SD) of the densitometric analysis of the ratio of specific proteins on α-Tubulin of three different experiments. 
(C) BC3 cells pre-treated or not with z-VAD (50 μM) were exposed to bortezomib at 20 nM for 24 hours and 
then analysed for K-bZIP expression by IFA. The percentage of K-bZIP expressing cells is also indicated. DAPI 
was used as nuclear staining.
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to exclude off-target effects of pharmacological treatments, we silenced ATG5 by specific siRNA in BC3 and Raji 
cells before bortezomib treatment. As shown in Fig. 3B, K-bZIP and ZEBRA expression was reduced by ATG5 
knock-down in comparison to scrumble siRNA, confirming the importance of the first phases of autophagy in 
bortezomib-induced lytic cycle.
Autophagy and gammaherpesvirus lytic cycle induction by bortezomib is dependent on JNK 
activation in the course of ER stress. Bortezomib has been reported to induce ER stress due to protea-
some inhibition and unfolded protein accumulation in the ER26. Accordingly, we previously demonstrated that 
ER stress was induced in a time-dependent manner in PEL cells undergoing bortezomib treatment. In this study, 
we investigated whether ER stress would occur concomitantly with viral replication and autophagy induction 
both in KSHV and as EBV-positive lymphoma cells treated with bortezomib13. As shown in Fig. 4A, B and C, the 
expression of BiP, CHOP and IRE1α (indicative of ER stress) increased in all cell lines studied, upon 24 hours of 
bortezomib treatment. ER stress can activate JNK that may induce autophagy12,13. Thus, we next evaluated JNK 
activation in KSHV and EBV-positive cells treated with bortezomib and its involvement in autophagy induc-
tion. As shown in Fig. 5A, although at different extent, JNK was hyper-phosphorylated in BC3 and B95-8 cell 
lines treated with bortezomib for 24 hours. Next, to investigate the role of JNK in bortezomib-induced KSHV 
and EBV lytic cycle and autophagy, JNK was inhibited by SP600125 specific inhibitor. We found that it strongly 
reduced either ZEBRA EBV lytic antigen and K-bZIP KSHV lytic antigen, as well as the autophagic marker 
LC3-II, in both B95-8 and BC3 cell lines (Fig. 5B and C), suggesting a pivotal role of JNK in promoting both 
processes. To confirm the importance of JNK in the induction of the viral lytic cycle and autophagy during borte-
zomib treatment, we transfected Raji and BCBL1 cells with HA-JNK-APF nonphosphorylatable mutant of JNK 
(DN-JNK) plasmid. As shown in Fig. 5D and E, both viral lytic antigen expression and autophagy was reduced 
in DN-JNK-transfected lymphoma cells in comparison with empty vector-transfected cells, upon bortezomib 
treatment. All together these results suggest that JNK promoted autophagy and lytic cycle in bortezomib-treated 
cells harboring gammaherpesvirus infection.
JNK is activated in lymphoma cells treated with thapsigargin as well as in stressful conditions in 
which gamma-herpesvirus reactivation occurs. We then assessed the activation and the role of JNK in 
KSHV lytic cycle activation by thapsigargin (Fig. 6A), another ER stressor known to promote gammaherpesvirus 
Figure 3. Bortezomib-induced autophagy promotes KSHV and EBV lytic cycle. (A) BC3 and Raji cells were 
treated with bortezomib in the presence or in the absence of 3-Methyladenine (3-MA) (5 mM) or chloroquine33 
(10 μM) and viral lytic antigen expression (K-bZIP and ZEBRA) was assessed after 24 hours of treatment 
by western blot analysis. (B) BC3 and Raji cells were silenced for ATG5 (siRNAATG5) or scramble-treated 
(siRNASC) for 48 hours and K-bZIP and ZEBRA expression was analyzed following 24 hours of bortezomib 
treatment. β-Actin was used as loading control. The histograms represent the mean plus standard deviation 
(SD) of the densitometric analysis of the ratio of specific proteins on β-Actin of three different experiments.
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reactivation from latency5,6. As shown in Fig. 6A, JNK inhibition by SP600125 reduced K-bZIP expression also in 
this context, suggesting that JNK plays a role also in the activation of viral lytic cycle triggered by this ER stressor. 
Furthermore, we next investigated whether JNK would be activated in B95–8 cells that detached from the plastic 
surface (B95-8d) and displayed an increased rate of spontaneous viral replication. The results shown in Fig. 6B 
demonstrated that JNK was hyper-phosphorylated in this cellular fraction (B95-8d) showing higher ZEBRA 
expression, likely because underwent to increased cell stress. All together these results suggest that the activation 
of JNK could be a common event in B cells undergoing gammaherpesvirus replication, either in spontaneous or 
induced conditions of cellular stress.
Discussion
This study shows that the activation of JNK may represent a molecular link between ER stress, autophagy and 
EBV and KSHV lytic cycle induction by bortezomib. We found indeed that JNK activation promoted both 
autophagy and viral lytic cycle in cells infected with gammaherpesviruses treated with bortezomib. It has been 
recently shown that bortezomib in combination with romidepsin induces an autophagic cell death in gastric 
carcinoma cells by activating MAPKs including JNK27. Interestingly bortezomib, already introduced in clinic 
use against multiple myeloma28, seems to be promising also for the therapy of PEL, an aggressive malignancy 
against which the traditional chemotherapies usually fail. Indeed, it has been reported that this drug can effi-
ciently trigger apoptosis in PEL cells29 that we then showed to be an immunogenic apoptosis, leading to the expo-
sure of several damage-associated molecular patterns (DAMPs)30. Later on, we showed the bortezomib induced 
ER stress and a pro-survival autophagy in PEL cells through the activation of JNK13. It is important, for cancers 
harboring onco-viruses such as KSHV and EBV, to investigate whether and how chemotherapies may affect viral 
replication. Indeed, if in one hand the onset of replication renders more efficient the use of antiviral agents, on 
the other hand, the replicative process facilitates viral spread, which might support maintenance/progression 
Figure 4. Bortezomib induces ER stress in lymphoma cells in which KSHV or EBV lytic cycle is activated. BC3, 
BCBL1, Raji and B95-8 cells were treated with bortezomib (BZ) (20 nM) and (A) BiP, (B) CHOP and (C) IRE1α 
expression was evaluated by western blot after 24 hours. The histograms represent the mean plus SD of the 
densitometric analysis of the ratio of specific proteins on β-Actin or α-Tubulin of three different experiments.
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of gammaherpesvirus-associated cancers23,24. Therefore, understanding the molecular mechanisms that regu-
late viral reactivation in the course of chemotherapy could help to avoid this unwanted effect. In this study, we 
found that the inhibition of JNK activation and autophagy could restrain lytic cycle induction by bortezomib in 
both EBV and KSHV-infected B cells. Similarly, we previously observed that the lytic cycle induction by TPA 
in combination with sodium butyrate (T/B) could be reduced by autophagy inhibition15,16. Here, we found that 
the inhibition of both autophagy and JNK activation reduced KSHV and EBV replication in bortezomib-treated 
cells. Interestingly, the inhibition of JNK and autophagy was previously shown to increase bortezomib-mediated 
cytotoxicity against PEL13. The finding of this study, showing that such inhibition can also reduce the viral rep-
licative cycle in KSHV as well as in EBV-associated lymphoma cells renders the use of these inhibitors in com-
bination with bortezomib even more promising in anticancer therapy. Gammaherpesvirus replication can be 
triggered by apoptotic stimuli although apoptosis has been shown to be neither necessary nor sufficient to induce 
such effect3. This study suggests that the activation of JNK and autophagy could represent possible links needed 
for initiating the viral replicative process in the course of treatment with cytotoxic drugs such as bortezomib. 
However, according to a previous study25, we found that the pan-caspase inhibitor zVAD was able to reduce viral 
lytic antigen expression. Since gammaherpesvirus replication is lytic, it is quite reasonable that it occurs in cells 
already committed to die. Indeed, it is possible that viruses exit from dying cells to infect new viable cells from 
Figure 5. JNK activated by bortezomib promotes gamma-herpesvirus lytic cycle through autophagy induction. 
(A) B95-8 and BC3 cells were treated with bortezomib (BZ) (20 nM) for 24 h and JNK phosphorylation 
(pJNK, p46 or p54) and total JNK expression (p46 or p54 isoforms) was investigated by western blotting. 
(B) B95-8 and (C) BC3 were pre-treated with SP600125 at 20 μM or mock-treated and then, cultured in the 
presence of bortezomib (BZ) (20 nM) for 24 hrs. EBV or KSHV lytic antigens ZEBRA and K-bZIP as well as 
LC3-I/II expression was analysed by western blotting. (D) Raji and (E) BCBL1 cells were transfected with 
nonphosphorylatable mutant JNK plasmid (DN-JNK) or with empty vector and then treated with bortezomib 
(BZ) (20 nM) for 24 h. The expression of ZEBRA, K-bZIP and LC3-I/II was evaluated by western blot. The 
histograms represent the mean plus SD of the densitometric analysis of the ratio of phosphorylated/total 
proteins or of specific proteins on β-Actin of three different experiments.
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which their survival is totally dependent. Another interesting finding of this study is that gammaherpesvirus 
replication is regulated by JNK activation also in other than bortezomib-induced stressful conditions. Indeed, 
we found that JNK was activated also during thapsigargin-induced ER stress and KSHV lytic cycle activation as 
well as in B95-8 cells undergoing spontaneous in vitro EBV replication. Cellular stress represent a physiological 
stimulus that triggers viral reactivation from latency in vivo, thus JNK activation is likely to be involved also in 
spontaneous gammaherpesvirus in vivo replication. Finally, in this study, we showed that although autophagy 
was involved in gammaherpesvirus replication, the last autophagic steps did not play a role in this process, likely 
because autophagy is blocked at its final steps during gammaherpesvirus replication15,24. It would be interesting 
to investigate whether JNK or other MAPKs manipulation could be overcame the autophagic block and push 
the autophagosomes, transporting the viral particles, into the lysosomes for viral degradation. In conclusion, by 
showing that JNK activation by bortezomib promotes autophagy and KSHV and EBV viral lytic cycle, this study 
suggests that combining JNK or autophagy inhibitors with bortezomib might be useful to reduce viral spread 
and likely to improve the outcome of bortezomib therapy against gamma-herpesvirus-associated malignancies.
Materials and Methods
Cells. BC3, BCBL1 (human B-cell lines derived from PEL carrying latent KSHV), Raji (human B cell line 
derived from BL carrying latent EBV) and B95-8 (marmoset B-cell line EBV-infected)31 were cultured in RPMI 
1640 (Sigma Aldrich), 10% Fetal Bovine Serum (FBS) (Sigma Aldrich), L-glutamine (Aurogene) and streptomy-
cin (100 μg/ml) and penicillin (100 U/ml) (Aurogene) in 5% CO2 at 37 °C.
Cell treatments. BC3, BCBL1, Raji and B95-8 cell lines were treated with bortezomib (BZ) (Santa Cruz 
Biotechnology Inc.) at 20 nM for 0, 4, 6, 24 hrs or mock treated. A dose-response experiment with 0-10-20 nM (for 
24 hours) was also performed in the same cell lines. In some experiments, BC3 were treated with Thapsigargin 
(5 μM) for 24 hrs. To evaluate the role of autophagy in viral replication, BC3 and Raji cell lines were cultured with 
bortezomib (20 μM) (Santa Cruz Biotechnology Inc.) in the presence or in the absence of chloroquine (10 μM) 
(Sigma Aldrich) or with 3-Methyladenine (3-MA) (5 mM) (Santa Cruz Biotechnology Inc.) for 24 hrs32,33. To 
further investigate autophagy, siRNAATG5 experiments were performed on the same cell line, as previously 
reported15.
In order to investigate the role of JNK, BC3 and B95-8 cell lines were pre-treated with SP600125 (SP, JNK 
inhibitor) (Santa Cruz Biotechnology Inc.) at 20 μM or Raji and BCBL1 cells were transfected with HA-JNK-APF 
nonphosphorylatable mutant of JNK (DN-JNK) plasmid or control vector13, and then cultured in presence of 
bortezomib (BZ) (20 nM) for 24 h.
In some experiments, cells were pretreated for 30 min with z-VAD pan caspase inhibitor (50 μM) (Santa Cruz 
Biotechnology Inc.) before exposure to bortezomib at 20 nM for 24 hours.
Antibodies. In this work to evaluate the expression of viral proteins we used: mouse monoclonal anti-K-bZIP 
(1:500) (Santa Cruz Biotechnology Inc.), rabbit polyclonal anti-ORF50-RTA (1:500) (kindly provided by Prof. 
D. Ganem)34, mouse monoclonal anti-ZEBRA (1:100) (Santa Cruz Biotechnology Inc.), anti-K8.1 (1:400) 
(Advanced Biotechnologies, 13-213-100) and anti gp350 (1:500) (ATCC 72A1). We also used the following 
Figure 6. JNK is hyper-phosphorylated in BC3 cells treated with thapsigargin and in B95-8 cells undergoing 
spontaneous viral replication. (A) BC3 cells were treated with thapsigargin (5 μM) for 24 h and JNK 
phosphorylation, total JNK (p46 or p54) and K-bZIP expression was evaluated by western blot analysis. (B) 
B95-8 adherents (a) or detached (d) were analyzed for JNK phosphorylation, total JNK (p46 and p54 isoforms) 
and ZEBRA expression by western blotting. The histograms represent the mean plus SD of the densitometric 
analysis of the ratio of phosphorylated/total proteins or of specific proteins on β-Actin of three different 
experiments.
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primary antibodies: rabbit polyclonal anti-BiP (1:100) (Cell Signaling), mouse monoclonal anti-CHOP (1:100) 
(Cell Signaling), mouse monoclonal anti-CHOP (1:100) (Santa Cruz Biotechnology Inc.), mouse monoclonal 
anti-IRE1α (1:100) (Santa Cruz Biotechnology Inc.), rabbit polyclonal anti-JNK (p46 and p54) (1:500) (Cell 
Signaling), rabbit polyclonal anti-pJNK (p46 and p54) (1:300) (Cell Signaling).
To study autophagy we used a rabbit polyclonal anti-LC3 (1:1000) (Novus Biologicals) and a rabbit polyclonal 
anti-ATG5 (1:500) (Novus Biologicals). Monoclonal mouse anti-β-actin (1:10000) (Santa Cruz Biotechnology 
Inc.) and monoclonal mouse anti-α-Tubulin (1:10000) (Santa Cruz Biotechnology Inc.) antibodies were used as 
a marker of equal loading. Goat polyclonal anti-mouse IgG-HRP (Santa Cruz Biotechnology Inc) and anti-rabbit 
IgG-HRP (Santa Cruz Biotechnology Inc.) were used as secondary antibodies. All the primary and secondary 
antibodies used in this study were diluted in a PBS- 0.1% Tween 20 solution containing 3% BSA.
Western blot. Cells (1 × 106) were washed twice with 1X PBS solution and centrifuged at 1500 rpm for 5 min-
utes. The pellet was lysed in a RIPA buffer containing 150 mM NaCl, 1% NP-40, 50 mM Tris-HCl (pH 8), 0.5% 
deoxycholic acid, 0.1% SDS, protease and phosphatase inhibitors. Then, 20 µg of protein lysates were subjected to 
electrophoresis on 4–12% NuPage Bis-Tris gels (Life Technologies) according to the manufacturer’s instruction. 
Then, the gels were transferred to Nitrocellulose Membranes (Biorad) for 2 hrs in Tris-Glycine. The membranes 
were blocked in PBS-0.1% Tween20 solution containing 3% of BSA, probed with specific antibodies and devel-
oped using ECL Blotting Substrate (Advansta)35.
ATG5 Knockdown by small interfering RNA. The knockdown of ATG5 (Santa Cruz Biotechnology, 
sc-41445) was performed in BC3 and Raji cell lines using specific small interfering RNA duplex. The day 
before transfection, 3 × 105 cells were seeded in 12-well culture plates in RPMI medium without antibiotics. 
Subsequently, 75 pmol of siRNA duplex and 7.5 µl of Lipofectamine 2000 Transfection Reagent (Life Technologies, 
11668027) were diluted in Optimem medium (Life Technologies, 31985062) and added to the cells for 48 hrs. 
Then, cells were treated with bortezomib (BZ) at 20 nM for 24 hrs.
The transfection efficiency was evaluated by a Fluorescein Conjugate-A siRNA (Santa Cruz Biotechnology, 
sc-36869), which was also used as a scrambled control.
Transfection and plasmids. We performed a transient transfection using HA-JNK-APF nonphosphoryl-
atable mutant of JNK (DN-JNK) plasmid or control vector in Raji and BCBL1 cell lines. Briefly, 5 × 105 cells were 
seeded into 24-well plates in RPMI medium without antibiotics and the day after, cells were transfected using 1 µg 
of plasmid DNA/well and with 2.5 µl of Lipofectamine 2000 transfection reagent 2000/well for 24 hrs, according 
to the manufacture’s instructions. Subsequently, cells were treated with bortezomib (BZ) (20 nM) for 24 hours 
and a western blot analysis was performed to evaluate ZEBRA (Raji cells) or K-bZIP (BCBL1 cells) and LC3-II 
proteins expression.
Densitometric Analysis. The quantification of proteins bands was performed by densitometric analysis 
using the Image J software (http://imagej.nih.gov).
Statistical analysis. Results are represented by the mean ± standard deviation (SD) of at least three inde-
pendent experiments.
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